US10208110B2ActiveUtilityA1
Compositions and methods related to recombinant antibodies to histone posttranslational modifications
Est. expiryJun 27, 2033(~6.9 yrs left)· nominal 20-yr term from priority
G01N 33/57557G01N 33/57535G01N 33/57525G01N 33/57515C07K 2317/92C07K 2317/565C07K 2317/622C07K 2317/55C07K 2317/33C07K 2317/21G01N 2800/50G01N 33/6875G01N 33/6812C07K 16/18G01N 33/57415G01N 33/57407G01N 33/57419G01N 33/57438
56
PatentIndex Score
0
Cited by
14
References
1
Claims
Abstract
Embodiments concern compositions and methods involving recombinant antibodies to histone post-translational modifications. The invention provides compositions and methods for histone methyltransferase assays. In certain embodiments, the compositions and methods involve a recombinant antibody that binds histone H3 fragment harboring biomarkers such as H3K9me3 mark, H3K4me3 mark, H3K36me3 mark, H3K27me3, H3K9me3 and H3S10phos or a recombinant antibody that binds histone H4 fragment harboring H4K20me3 mark.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A purified recombinant polypeptide comprising a variable heavy chain region comprising the sequence of complementarity determining regions (CDR) CDR-H1, CDR-H2, and CDR-H3 of the 309M3-B antibody and a variable light chain region comprising the sequence of complementarity determining regions CDR-L1, CDR-L2, and CDR-L3 of the 309M3-B antibody, wherein the polypeptide bind to H3K9me3.Join the waitlist — get patent alerts
Track US10208110B2 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.